Salubris pharmaceuticals plans H-share issuance and hong kong listing

Shenzhen Salubris Pharmaceuticals Co., Ltd. announced plans to issue H-shares and list them on The Stock Exchange of Hong Kong Limited. This strategic initiative aims to advance the company's globalization strategy and build an international capital operation platform, supporting its high-quality development. Discussions with intermediary agencies regarding the specific implementation of the listing are ongoing, and details are not yet finalized. The company clarified that this move will not alter its controlling shareholder or actual controller.

The proposed H-share issuance and listing are subject to various approvals, including review by the company's board of directors and shareholders,备案 with the China Securities Regulatory Commission, and approval from The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission of Hong Kong. This process will adhere to regulations such as the Company Law of the People's Republic of China and the Securities Law of the People's Republic of China.

Salubris Pharmaceuticals emphasized that the successful completion of the issuance and listing remains highly uncertain. The company commits to timely disclosure of information and adherence to regulatory requirements. Investors are advised to monitor subsequent announcements and exercise caution due to the inherent uncertainties.